Related to Enzo Sues Roche, Gen-Probe, and Life Technologies in Patent Infringement Case

• USPTO Tasked with Evaluating Impact of Gene Patents on Second-Opinion Testing
  Diagnostic firms argue IP protection is key to innovation, while their opponents say it hurts medical practice.
  
• R&D Direction in 2012 for Sequencing Technologies Is Aimed at Clinical Medicine
  Companies are focused on making these platforms smaller and easier to use.
  
• Standardization Key to Taking Next-Generation Sequencing to the Next Level
  As NGS technology makes steady progress with faster and cheaper machines, regulation will have to keep up.
  
• Japan and Australia to Institute Changes to Patent System This Year
  Amendments in Japan take effect in April, and approval of the Australian bill is expected mid-year.
  
• Debate over Patenting Genes at Forefront of First Hearing on Second Opinion Testing
  Hearing was part of a study required by the new patent system to assess the impact of gene patents on obtaining confirmatory tests.
  
• Sequencing in the Dark
  Analysis of Life Technologies’ Ion Torrent sequencing platform points to significance of photon-free technology.
  
• Roche, Illumina Duke It Out in Potential $5.7B Takeover Deal
  Roche’s hostile $44.50 per share bid could also spark additional sequencing acquisition wars.
  
• Will Roche Really Drop Illumina and Seek out Another Sequencing Firm?
  Oxford Nanopore and PacBio both have exciting technologies, but Illumina remains market leader.
  
• Filings Postponed in Promega v. Life Tech as Parties Try to Settle
  Last month a jury awarded Promega $52 million in damages related to firm’s short tandem repeat technology.
  
• Myriad, Prometheus Continue to Defend Diagnostic Patents while Others Urge More Licensing
  Battle raged on at second USPTO hearing tasked with evaluating the impact of patents on the availability of confirmatory tests.
  
• Illumina, Complete Genomics Prepare for Legal Battle over Sequencing IP
  Illumina filed the case stating that the Complete Genomics Analysis Platform infringes on three of its patents.
  
• EPO Decision, Utah Litigation Show Tuschl Patents Remain Mired in Litigation
  Just as the dust settled in Europe regarding Alnylam’s Tuschl I claims, a lawsuit contesting Tuschl II ownership in the U.S. has risen.
  
• This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
  Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.
  
• LAVAgel for Protein Diagnostics
  Researchers introduce a microfluidic, single-channel, multistage immunoblotting strategy toward scalable protein isoform analysis.
  
• Genome Testing Reduces Overtreatment
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.
  
• Biggest Biotech Trends of 2012
  GEN takes a look back at some key biopharma developments of the past 12 months.
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• Top 10 Biggest Biopharma Marketing Fines
  Find out which companies have made false claims about their products—and are paying the most for it now.
  
• DNA Collection v. DNA Privacy
  Supreme Court weighs constitutionality of taking samples from arrested suspects absent a conviction.
  
• GMO Rider: ‘Monsanto Protection’ or ‘Farmer Sustainability’?
  As Washington embraces GMOs, opponents look to studies, states, and retailers for support.